SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-24-098328
Filing Date
2024-11-14
Accepted
2024-11-14 15:32:57
Documents
1
Group Members
GUY LEVYSOLEUS CAPITAL GROUP, LLCSOLEUS CAPITAL MANAGEMENT, L.P.SOLEUS CAPITAL MASTER FUND, L.P.SOLEUS CAPITAL, LLCSOLEUS GP, LLCSOLEUS PE GP III, LLCSOLEUS PRIVATE EQUITY GP III, LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO SCHEDULE 13G ea0221047-13ga2soleus3_jas.htm SC 13G/A 190354
  Complete submission text file 0001213900-24-098328.txt   192378
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Subject) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-91228 | Film No.: 241461051
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 104 FIELD POINT ROAD, 2ND FLOOR GREENWICH CT 06830
Business Address 104 FIELD POINT ROAD, 2ND FLOOR GREENWICH CT 06830 475-208-3178
Soleus Private Equity Fund III, L.P. (Filed by) CIK: 0001955982 (see all company filings)

IRS No.: 880637097 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A